Patent intelligence · US
US 11433038
High concentration medicant solutions for treating neurological disorders
High concentration medicant solutions for treating neurological disorders
Patent details — US 11433038
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 6, 2022
- Expiration
- Sep 1, 2042
- Claims
- 16
- CPC classes
- A61K, A61K31/19, A61K45/06, A61K47/12
Quick answer
US 11433038 (High concentration medicant solutions for treating neurological disorders) is held by The Regents of the University of Colorado. Status: granted. Granted Sep 6, 2022. Expires Sep 1, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/19, A61K45/06, A61K47/12, A61K9/0019, A61K9/0085
More from The Regents of the University of Colorado
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 11433038?
US 11433038 (High concentration medicant solutions for treating neurological disorders) is held by The Regents of the University of Colorado. Status: granted. Granted Sep 6, 2022. Expires Sep 1, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11433038?
The Regents of the University of Colorado is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11433038 expire?
Our index shows an expiration date of Sep 1, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.